Medically reviewed by Erika Prouty, PharmD Key Takeaways There are two types of complement 3 glomerulopathy: dense deposit ...

The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...

Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care BLA Submission with U.S./European Data from ...

Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...

Performances in N.Y.C. Advertisement Supported by Thinking outside the canon, and finding the gritty and the beautiful, within it. By Joshua Barone and Corinna da Fonseca-Wollheim JOSHUA BARONE Few ...

In 2019 I wrote about research suggesting anti-inflammatory medications might help some people with major depression. At the time, the idea that depression could have roots in the immune system felt ...

The classical pathway for complement activation is initiated by the formation of a complex between C1q and an antigen-antibody complex, setting off a cascade of proteolytic events that culminate in ...

ATLANTA — Residents in a Buckhead senior community said they've endured two sleepless nights due to loud classical music and flashing blue lights coming from a mobile surveillance system installed in ...

– Single subcutaneous dose of ADX-038 achieved near-complete alternative pathway suppression for 6 months, supporting potent and selective CFB silencing – – Phase 2 studies are ongoing to assess the ...

SAN FRANCISCO -- The investigational complement-targeting agent claseprubart was safe and led to significant improvements in generalized myasthenia gravis (MG), the phase II MaGic trial showed. The ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...